

II. REMARKS

Restriction Requirement

Claims 1-15 are pending. The Examiner has required restriction of the claims to one of the following groups under 35 U.S.C. §121:

- I. Claims 6-9 and 14-15, drawn to a method for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need comprising administering to the mammal a therapeutic compound which binds to a cell surface receptor on a target mammalian cell wherein the therapeutic compound is an antibody against CD11a.
- II. Claim 6, drawn to a method for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need comprising administering to the mammal a therapeutic compound which binds to a cell surface receptor on a target mammalian cell wherein the therapeutic compound is an antibody against CD18.

Claims 1-5 and 10-13 are linking claims and will be examined along with elected Group I or II.

In response to the restriction requirement, Applicants hereby elect, without traverse, the invention of Group I, claims 6-9 and 14-15 for further prosecution. Applicants expressly reserve the right under 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of the instant application.

Species Election

The Examiner has further required election of a specific disease such as those recited in claims 14 and 15 (i.e., psoriasis, asthma, transplant rejection, rheumatoid arthritis, SLE or MS).

With regard to the requirement to elect a specific disease, applicants hereby elect psoriasis. All claims are readable upon the elected species.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Director to charge the cost of such petitions and/or other fees due in connection with the filing of this document to our Deposit Account No. 07-0630.

Respectfully submitted,
GENENTECH, INC.

Date: August 6, 2004

By: Lee K. Tan
Lee K. Tan, Ph.D.
Reg. No. 39,447
Phone: (650)225-4462

Doc. #160799